NASDAQ:NTECIntec Pharma Stock Price, Forecast & News

$0.38

-0.04 (-9.52 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.35

Now: $0.38▼

$0.40

50-Day Range

$0.21

MA: $0.26▼

$0.42

52-Week Range

$0.13

Now: $0.38▼

$5.20

Volume14.31 million shs

Average Volume14.03 million shs

Market Capitalization$20.13 million

P/E RatioN/A

Dividend YieldN/A

Beta0.75

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.

Beat the Market (BTM) Rank^™

3.0 Analyst's Opinion

Consensus Rating
Intec Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Intec Pharma has a potential upside of 2,794.7% from its current price of $0.38.
Amount of Analyst Coverage
Intec Pharma has only been the subject of 2 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Intec Pharma has received 277 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Intec Pharma has received 307 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Intec Pharma has received 52.57% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote “Outperform” if you believe NTEC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Intec Pharma does not currently pay a dividend.
Dividend Growth
Intec Pharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intec Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.90% of the stock of Intec Pharma is held by insiders.
Percentage Held by Institutions
Only 11.36% of the stock of Intec Pharma is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Intec Pharma are expected to grow in the coming year, from ($0.23) to ($0.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intec Pharma is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intec Pharma is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intec Pharma has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.21 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NTEC

Previous Symbol

CUSIPN/A

CIK1638381

Webwww.intecpharma.com

Phone972-2586-4657

Debt

Debt-to-Equity RatioN/A

Current Ratio2.64

Quick Ratio2.64

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.22 per share

Price / Book1.73

Profitability

EPS (Most Recent Fiscal Year)($1.09)

Net Income$-47,600,000.00

Net MarginsN/A

Return on Equity-142.81%

Return on Assets-93.59%

Miscellaneous

Employees38

Outstanding Shares52,970,000

Market Cap$20.13 million

Next Earnings Date8/14/2020 (Estimated)

OptionableOptionable

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter.

Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

How has Intec Pharma's stock been impacted by COVID-19 (Coronavirus)?

Intec Pharma's stock was trading at $0.2388 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NTEC stock has increased by 59.1% and is now trading at $0.38. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Intec Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Intec Pharma.

When is Intec Pharma's next earnings date?

Intec Pharma is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Intec Pharma.

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) issued its earnings results on Monday, May, 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.01. View Intec Pharma's earnings history.

What price target have analysts set for NTEC?

5 analysts have issued 12-month target prices for Intec Pharma's stock. Their forecasts range from $1.00 to $16.00. On average, they anticipate Intec Pharma's stock price to reach $11.00 in the next year. This suggests a possible upside of 2,794.7% from the stock's current price. View analysts' price targets for Intec Pharma.

What are Wall Street analysts saying about Intec Pharma stock?

Here are some recent quotes from research analysts about Intec Pharma stock:

1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (3/24/2020)
2. LADENBURG THALM/SH SH analysts commented, "We are modeling mid-’19 cash is sufficient to fund operations till late 2020. While we appreciate Accordion Pill’s controlled-release abilities and still find AP-CBD/THC’s PK results vs. Sativex as impressive (290-330% and 25-50% higher exposures of CBD and THC, respectively, than Sativex), we have little insight into how the AP-Novartis Phase 1 may come out. Intec’s collaboration on an undisclosed compound was announced. Intec reported it successfully developed an a proprietary Novartis compound that met the prerequisite in vitro specifications. In 1Q’19 a human PK began, with the expectation for completion of the study and the results this summer, with Novartis making a go/no-go decision on a Phase 2 this fall." (8/12/2019)
3. Maxim Group analysts commented, "Intec announced the presentation of the results from its PK study on AP-CD/ LD (Accordion Pill – Carbidopa/Levodopa) in Parkinson’s disease (PD) at the XXIV Related Disorders. The data was originally reported on 2/19 (see note, LINK), however, additional detail was provided in the presentation." (6/20/2019)

Has Intec Pharma been receiving favorable news coverage?

Headlines about NTEC stock have trended positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intec Pharma earned a news sentiment score of 2.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutIntec Pharma.

Who are some of Intec Pharma's key competitors?

Some companies that are related to Intec Pharma include Leap Therapeutics (LPTX), Milestone Pharmaceuticals (MIST), SCYNEXIS (SCYX), Sesen Bio (SESN), Celsion (CLSN), Monopar Therapeutics (MNPR), Oncolytics Biotech (ONCY), Assertio Therapeutics (ASRT), CTI BioPharma (CTIC), Bellerophon Therapeutics (BLPH), Oramed Pharmaceuticals (ORMP), ContraFect (CFRX), CV Sciences (CVSI), resTORbio (TORC) and Onconova Therapeutics (ONTX). View all competitors.

What other stocks do shareholders of Intec Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Canopy Growth (CGC), Nabriva Therapeutics (NBRV), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO) and Verastem (VSTM).

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the following people:

Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 53, Pay $786.9k)
Mr. Nir Sassi, Chief Financial Officer (Age 44, Pay $338.11k)
Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 51, Pay $394.94k)
Mr. Walt Addison Linscott, Chief Bus. Officer (Age 59, Pay $557.05k)
Dr. R. Michael Gendreau, Chief Medical Officer (Age 64, Pay $459.15k)

When did Intec Pharma IPO?

(NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

Who are Intec Pharma's major shareholders?

Intec Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Phoenix Holdings Ltd. (1.13%). Company insiders that own Intec Pharma stock include Anthony J Maddaluna, Issac Silberman, Jeffrey A Meckler and Pharma Technologies Ltd Dexcel. View institutional ownership trends for Intec Pharma.

Which major investors are buying Intec Pharma stock?

NTEC stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd.. Company insiders that have bought Intec Pharma stock in the last two years include Anthony J Maddaluna, and Jeffrey A Meckler. View insider buying and selling activity for Intec Pharma.

How do I buy shares of Intec Pharma?

Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intec Pharma's stock price today?

One share of NTEC stock can currently be purchased for approximately $0.38.

How big of a company is Intec Pharma?

Intec Pharma has a market capitalization of $20.13 million. The biotechnology company earns $-47,600,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Intec Pharma employs 38 workers across the globe.

What is Intec Pharma's official website?

The official website for Intec Pharma is www.intecpharma.com.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff